Association of Lactate Dehydrogenase and Predictive Biomarkers in Primary Lung and Breast Tumors with Metastatic Bone Disease
DOI:
https://doi.org/10.37287/ijghr.v8i1.672Keywords:
biomarkers, lactate dehydrogenase, metastatic bone disease, primary lung tumor, primary breast tumorAbstract
Metastatic Bone Disease (MBD) is one of the most aggressive forms of tumor spread, reshaping the tumor microenvironment into a hypoxic and acidic state that enhances lactate dehydrogenase (LDH) activity. Primary lung and breast tumors possess distinct predictive biomarkers, EGFR and HER2, which drive the Warburg effect and further elevate LDH levels. MBD often leads to skeletal-related events that impair quality of life and require prompt, comprehensive management. This study aimed to examine the the association between LDH levels and EGFR/HER2 expression, and evaluate LDH’s potential as an early, efficient indicator for clinical decision-making in MBD patients. Method: A cross-sectional study was conducted through medical record reviews at Dr. Moewardi General Hospital, Surakarta. Samples included patients with primary lung and breast tumors diagnosed with MBD from 2023–2024, selected using total sampling. Serum LDH, EGFR, and HER2 data were then retrieved from the electronic medical record. Associations between LDH and EGFR/HER2 were analyzed using binary logistic regression. LDH showed a positive but statistically non-significant association with EGFR mutation status in lung cancer patients with MBD (OR=0.999, 95% CI=0.994–1.004, p=0.713) and with HER2 status in breast cancer patients with MBD (OR=1.750, 95% CI=0.084–36.287, p=0.718). LDH was positively associated with EGFR and HER2 expression in MBD patients, though the associations were not statistically significant.
References
Armando, B., Setiawati, R., Edward, M., & Mustokoweni, S. (2023). Conventional Radiological Profile of Metastatic Bone Disease Based on Its Histopathological Results: A 3-Year Experience. JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga, 14(2), 76–82. https://doi.org/10.20473/juxta.v14i22023.76-82
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., Hoshino, T., Nakanishi, Y., & Okamoto, I. (2014). Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Annals of Oncology, 25(10), 1935–1940. https://doi.org/10.1093/annonc/mdu242
Chan, S. W. S., Smith, E., Aggarwal, R., Balaratnam, K., Chen, R. Q., Hueniken, K., Fazelzad, R., Weiss, J., Jiang, S., Shepherd, F. A., Bradbury, P. A., Sacher, A. G., Leighl, N. B., Xu, W., Brown, M. C., Eng, L., & Liu, G. (2021). Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical Lung Cancer, 22(5), 390–407. https://doi.org/10.1016/j.cllc.2021.01.002
Christ, A. B., Piple, A. S., Gettleman, B. S., Duong, A., Chen, M., Wang, J. C., Heckmann, N. D., & Menendez, L. (2023). Prevalence of primary malignant tumours, rates of pathological fracture, and mortality in the setting of metastatic bone disease. Bone & Joint Open, 4(6). https://doi.org/10.1302/2633-1462.46.BJO
Dalkir, K. A., Mirioglu, A., Kundakci, B., Bagir, M., Deveci, M. A., & Ozbarlas, H. S. (2024). Prognostic factors and real-life applicability of prognostic models for patients with bone metastases of carcinoma. Acta Orthopaedica et Traumatologica Turcica, 58(1), 62–67. https://doi.org/10.5152/j.aott.2024.23132
Dean, A. G., Sullivan, K. M., & Soe, M. M. (2013). OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 3. https://www.openepi.com/Menu/OE_Menu.htm
Feng, Z., Ou, Y., & Hao, L. (2022). The roles of glycolysis in osteosarcoma. In Frontiers in Pharmacology (Vol. 13). Frontiers Media S.A. https://doi.org/10.3389/fphar.2022.950886
Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: current researches in cancer. In Am J Cancer Res (Vol. 10, Issue 3). www.ajcr.us/
Huang, B., Wu, F. C., Wang, W. D., Shao, B. Q., Wang, X. M., Lin, Y. M., Zheng, G. X., Dong, M. M., Liu, C. T., Xu, Y. W., & Wang, X. J. (2023). The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission. Annals of Medicine, 55(1). https://doi.org/10.1080/07853890.2023.2231342
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024). Regulatory mechanisms of PD-1/PD-L1 in cancers. In Molecular Cancer (Vol. 23, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12943-024-02023-w
Masruroh F. (2019) Hubungan kadar lactate dehidrogenase cairan efusi pleura dengan status HER2 pada kanker payudara metastasis pleura. JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga, 14(2), 76–82. https://doi.org/10.20473/juxta.v14i22023.76-82
Morris, C. D., & LiBrizzi, C. L. (2021). Context and Approach to Metastatic Bone Disease. Operative Techniques in Orthopaedics, 31(3). https://doi.org/10.1016/j.oto.2021.100892
Onken, J. S., Fekonja, L. S., Wehowsky, R., Hubertus, V., & Vajkoczy, P. (2019). Metastatic dissemination patterns of different primary tumors to the spine and other bones. Clinical & Experimental Metastasis, 36(6), 493–498. https://doi.org/10.1007/s10585-019-09987-w
Oprea-Lager, D. E., Cysouw, M. C. F., Boellaard, R., Deroose, C. M., de Geus-Oei, L. F., Lopci, E., Bidaut, L., Herrmann, K., Fournier, L. S., Bäuerle, T., deSouza, N. M., & Lecouvet, F. E. (2021). Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. In Frontiers in Oncology (Vol. 11). Frontiers Media S.A. https://doi.org/10.3389/fonc.2021.772530
Pelizzari, G., Basile, D., Zago, S., Lisanti, C., Bartoletti, M., Bortot, L., Vitale, M. G., Fanotto, V., Barban, S., Cinausero, M., Bonotto, M., Gerratana, L., Mansutti, M., Curcio, F., Fasola, G., Minisini, A. M., & Puglisi, F. (2019). Lactate Dehydrogenase (LDH) response to first-line treatment predicts survival in metastatic breast cancer: First clues for a cost-effective and dynamic biomarker. Cancers, 11(9). https://doi.org/10.3390/cancers11091243
Pérez-Tomás, R., & Pérez-Guillén, I. (2020). Lactate in the tumor microenvironment: An essential molecule in cancer progression and treatment. In Cancers (Vol. 12, Issue 11, pp. 1–29). MDPI AG. https://doi.org/10.3390/cancers12113244
Terracina, S., Ferraguti, G., Petrella, C., Bruno, S. M., Blaconà, G., Di Certo, M. G., Minni, A., Greco, A., Musacchio, A., Ralli, M., Tarani, L., Ceccanti, M., Polimeni, A., Triaca, V., & Fiore, M. (2023). Characteristic Hallmarks of Aging and the Impact on Carcinogenesis. Current Cancer Drug Targets, 23(2), 87–102. https://doi.org/10.2174/1568009622666220816120353
Todd, V. M., & Johnson, R. W. (2020). Hypoxia in bone metastasis and osteolysis. In Cancer Letters (Vol. 489, pp. 144–154). Elsevier Ireland Ltd. https://doi.org/10.1016/j.canlet.2020.06.004
Wiksa Astrayana, I. G. A., & Astawa, P. (2024). Patient Characteristics of Secondary Metastatic Bone Disease Due to Primary Lung Cancer in Prof. Dr. IGNG Ngoerah Hospital During 2016-2021: A Descriptive Study. International Journal of Research and Review, 11(5), 167–176. https://doi.org/10.52403/ijrr.20240521
Wróbel, A., Vandenberghe, M., Scott, M., Jones, F., Matsuo, T., Boothman, A. M., Whiteley, J., & Barker, C. (2025). Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff: HER2 IHC scoring concordance in breast cancer. Diagnostic Pathology , 20(1). https://doi.org/10.1186/s13000-025-01624-3
Zhang, J., & Wu, J. (2021). The Potential Roles of Exosomal miR-214 in Bone Metastasis of Lung Adenocarcinoma. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.611054
Zhi, S., Chen, C., Huang, H., Zhang, Z., Zeng, F., & Zhang, S. (2024). Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment. In Frontiers in Immunology (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fimmu.2024.1370800
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
